Current evidence for histone deacetylase inhibitors in pancreatic cancer

World Journal of Gastroenterology

Volumn 19, Issue 6, 2013, Pages 813-828

  Koutsounas, Ioannis ^a   Giaginis, Constantinos ^a,b   Patsouris, Efstratios ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

Author keywords

Experimental studies; Histone deacetylase inhibitors; Histone deacetylases; Pancreatic cancer

Indexed keywords

4 PHENYLBUTYRIC ACID; BORTEZOMIB; BUTYRIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1C; ENTINOSTAT; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MASPIN; MEMBRANE METALLOENDOPEPTIDASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOCETINOSTAT; MUCIN; NVPLBH 589; OXALIPLATIN; PANOBINOSTAT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN P21; PROTEIN P27; ROMIDEPSIN; SORAFENIB; TACEDINALINE; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CANCER INHIBITION; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DOWN REGULATION; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; NONHUMAN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84873724224     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i6.813     Document Type: Review

References (113)

1. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699-708. [PMID: 19806144 DOI: 10.1038/nrgastro.2009.17]
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617. [PMID: 20427809 DOI: 10.1056/NEJMra0901557]
3. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK. SEER Cancer Statistics Review, 1975-2000. National Cancer Institute, 2003
4. Micke O, Hesselmann S, Bruns F, Horst E, Devries A, Schüller P, Willich N, Schäfer U. Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 2005; 25: 1523-1530. [PMID: 16033054]
5. Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K. A randomised, prospective, multicenter, phase iii trial of gemcitabine, 5-fluorouracil (5-fu), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 4009
6. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-3783. [PMID: 15365074 DOI: 10.1200/JCO.2004.12.082]
7. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785. [PMID: 19581537 DOI: 10.1200/JCO.2008.20.9007]
8. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645. [PMID: 16087696 DOI: 10.1093/annonc/mdi309]
9. Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006; 24: 4441-4447. [PMID: 16983112 DOI: 10.1200/JCO.2006.07.0201]
10. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Sc H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952. [PMID: 16921047 DOI: 10.1200/JCO.2005.05.1490]
11. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518. [PMID: 19858379 DOI: 10.1200/JCO.2009.24.2446]
12. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825. [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]
13. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]
14. Rocha-Lima CM. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 2008; 19: 435-446. [PMID: 18418211]
15. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007; 128: 669-681. [PMID: 17320505 DOI: 10.1016/j.cell.2007.01.033]
16. Kouraklis G, Theocharis S. Histone acetylation and cancer. Acta Oncol 2003; 42: 792. [PMID: 14690169]
17. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31. [PMID: 15050820 DOI: 10.1016/j.jmb.2004.02.006]
18. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625: 131-142. [PMID: 19836388 DOI: 10.1016/j.ejphar.2009.10.011]
19. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107: 600-608. [PMID: 19459166 DOI: 10.1002/jcb.22185]
20. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009; 41: 199-213. [PMID: 18790076 DOI: 10.1016/j.biocel.2008.08.020]
21. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552. [PMID: 17694093 DOI: 10.1038/sj.onc.1210620]
22. Kouraklis G, Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep 2006; 15: 489-494. [PMID: 16391874]
23. Kouraklis G, Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anticancer Agents 2002; 2: 477-484. [PMID: 12678732]
24. Codd R, Braich N, Liu J, Soe CZ, Pakchung AA. Zn(II) dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol 2009; 41: 736-739. [PMID: 18725319 DOI: 10.1016/j.biocel.2008.05.026]
25. Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, Scarpa A, Palmieri M. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003; 38: 59-69. [PMID: 14502645 DOI: 10.1002/mc.10145]
26. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both proand anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 2004; 1693: 167-176. [PMID: 15363630 DOI: 10.1016/j.bbamcr.2004.07.001]
27. Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65: 2344-2352. [PMID: 15781649 DOI: 10.1158/0008-5472. CAN-04-3502]
28. García-Morales P, Gómez-Martínez A, Carrato A, MartínezLacaci I, Barberá VM, Soto JL, Carrasco-García E, Menéndez-Gutierrez MP, Castro-Galache MD, Ferragut JA, Saceda M. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 2005; 4: 1222-1230. [PMID: 16093438 DOI: 10.1158/1535-7163.MCT-04-0186]
29. Ryu JK, Lee WJ, Lee KH, Hwang JH, Kim YT, Yoon YB, Kim CY. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 2006; 237: 143-154. [PMID: 16009488 DOI: 10.1016/j.canlet.2005.05.040]
30. Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 2006; 348: 1245-1253. [PMID: 16904634 DOI: 10.1016/j.bbrc.2006.07.185]
31. Cecconi D, Donadelli M, Rinalducci S, Zolla L, Scupoli MT, Scarpa A, Palmieri M, Righetti PG. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics 2007; 7: 1644-1653. [PMID: 17443844 DOI: 10.1002/pmic.200600811]
32. Cecconi D, Donadelli M, Dalla Pozza E, Rinalducci S, Zolla L, Scupoli MT, Righetti PG, Scarpa A, Palmieri M. Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics 2009; 9: 1952-1966. [PMID: 19294695 DOI: 10.1002/pmic.200701089]
33. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007; 1773: 1095-1106. [PMID: 17555830 DOI: 10.1016/j.bbamcr.2007.05.002]
34. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C. The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol 2007; 31: 567-576. [PMID: 17671683]
35. Zhang S, Cai X, Huang F, Zhong W, Yu Z. Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. Exp Oncol 2008; 30: 265-268. [PMID: 19112422]
36. Ouaïssi M, Cabral S, Tavares J, da Silva AC, Mathieu Daude F, Mas E, Bernard J, Sastre B, Lombardo D, Ouaissi A. Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 2008; 7: 523-531. [PMID: 18296916]
37. Ammanamanchi S, Freeman JW, Brattain MG. Acetylated sp3 is a transcriptional activator. J Biol Chem 2003; 278: 35775-35780. [PMID: 12837748 DOI: 10.1074/jbc.M305961200]
38. Zhao S, Venkatasubbarao K, Li S, Freeman JW. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. Cancer Res 2003; 63: 2624-2630. [PMID: 12750289]
39. Huang W, Zhao S, Ammanamanchi S, Brattain M, Venkatasubbarao K, Freeman JW. Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J Biol Chem 2005; 280: 10047-10054. [PMID: 15647279 DOI: 10.1074/jbc.M408680200]
40. Bhakat KK, Mitra S. Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. J Biol Chem 2000; 275: 34197-34204. [PMID: 10942771 DOI: 10.1074/jbc.M005447200]
41. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735-3742. [PMID: 12839967]
42. Cecconi D, Scarpa A, Donadelli M, Palmieri M, Hamdan M, Astner H, Righetti PG. Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. Electrophoresis 2003; 24: 1871-1878. [PMID: 12783462 DOI: 10.1002/elps.200305430]
43. Marengo E, Robotti E, Cecconi D, Hamdan M, Scarpa A, Righetti PG. Identification of the regulatory proteins in human pancreatic cancers treated with Trichostatin A by 2D-PAGE maps and multivariate statistical analysis. Anal Bioanal Chem 2004; 379: 992-1003. [PMID: 15257427 DOI: 10.1007/s00216-004-2707-x]
44. Ohike N, Maass N, Mundhenke C, Biallek M, Zhang M, Jonat W, Lüttges J, Morohoshi T, Klöppel G, Nagasaki K. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 2003; 199: 193-200. [PMID: 12969792]
45. Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2004; 23: 1531-1538. [PMID: 14716296 DOI: 10.1038/sj.onc.1207269]
46. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C, Goggins M. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63: 4158-4166. [PMID: 12874021]
47. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005; 11: 4681-4688. [PMID: 16000561 DOI: 10.1158/1078-0432.CCR-04-2471]
48. Vincent A, Perrais M, Desseyn JL, Aubert JP, Pigny P, Van Seuningen I. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007; 26: 6566-6576. [PMID: 17471237 DOI: 10.1038/sj.onc.1210479]
49. Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, Yonezawa S. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 2006; 119: 1850-1857. [PMID: 16721789 DOI: 10.1002/ijc.22047]
50. Vincent A, Ducourouble MP, Van Seuningen I. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. FASEB J 2008; 22: 3035-3045. [PMID: 18492726 DOI: 10.1096/fj.07-103390]
51. Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, Goggins MG, Mendell JT, Maitra A. Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009; 9: 293-301. [PMID: 19407485 DOI: 10.1159/000186051]
52. Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006; 448: 797-804. [PMID: 16568310 DOI: 10.1007/s00428-006-0173-x]
53. Lee S, Shinji C, Ogura K, Shimizu M, Maeda S, Sato M, Yoshida M, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2007; 17: 4895-4900. [PMID: 17588744 DOI: 10.1016/j.bmcl.2007.06.038]
54. Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007; 13: 18-26. [PMID: 17200334 DOI: 10.1158/1078-0432.CCR-06-0914]
55. Neureiter D, Zopf S, Leu T, Dietze O, Hauser-Kronberger C, Hahn EG, Herold C, Ocker M. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 2007; 42: 103-116. [PMID: 17190770 DOI: 10.1080/0036552060 0874198]
56. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121: 656-665. [PMID: 17417771 DOI: 10.1002/ijc.22558]
57. Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 2009; 76: 327-341. [PMID: 19483105 DOI: 10.1124/mol.109.056309]
58. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 2008; 14: 5385-5399. [PMID: 18765530 DOI: 10.1158/1078-0432.CCR-08-0469]
59. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008; 7: 1648-1662. [PMID: 18787411]
60. Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 2009; 8: 1328-1339. [PMID: 19421011]
61. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66: 3773-3781. [PMID: 16585204 DOI: 10.1158/0008-5472.CAN-05-2961]
62. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 2006; 130: 548-565. [PMID: 16472607 DOI: 10.1053/j.gastro.2005.11.008]
63. Deorukhkar A, Park H, Shentu S, Diagaradjane P, Krishnan S. Vorinostat radiosensitizes pancreatic cancers by inhibiting DNA repair and radiation-induced EGFR and NF-KB signaling. Pancreas 2007; 35: 398-399
64. Kajiwara Y, Panchabhai S, Liu DD, Kong M, Lee JJ, Levin VA. Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. Technol Cancer Res Treat 2009; 8: 163-176. [PMID: 19334798]
65. Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, Imai Y, Song JH, Gui D, Said J, Koeffler HP. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 2009; 124: 827-833. [PMID: 19035457 DOI: 10.1002/ijc.23994]
66. Lehmann A, Denkert C, Budczies J, Buckendahl AC, DarbEsfahani S, Noske A, Müller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009; 9: 395. [PMID: 19912635 DOI: 10.1186/1471-2407-9-395]
67. Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 2010; 10: 997-1008. [PMID: 20645688 DOI: 10.1586/era.10.88]
68. Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 2004; 24: 679-685. [PMID: 14767553]
69. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosisinducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006; 66: 7317-7325. [PMID: 16849582 DOI: 10.1158/0008-5472.CAN-06-0680]
70. Wu LP, Wang X, Li L, Zhao Y, Lu S, Yu Y, Zhou W, Liu X, ang J, Zheng Z, Zhang H, Feng J, Yang Y, Wang H, Zhu WG. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol 2008; 28: 3219-3235. [PMID: 18332107 DOI: 10.1128/MCB.01516-07]
71. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978. [PMID: 11742974 DOI: 10.1093/emboj/20.24.6969]
72. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008; 34: 206-222. [PMID: 18226465 DOI: 10.1016/j.ctrv.2007.11.003]
73. Erhuma M, Köbel M, Mustafa T, Wulfänger J, Dralle H, Hoang-Vu C, Langner J, Seliger B, Kehlen A. Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. Int J Cancer 2007; 120: 2393-2400. [PMID: 17294442 DOI: 10.1002/ijc.22252]
74. Jones J, Bentas W, Blaheta RA, Makarevic J, Hudak L, Wedel S, Probst M, Jonas D, Juengel E. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 2008; 22: 293-299. [PMID: 18698487]
75. Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, Schmid RM, Saur D, Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009; 58: 1399-1409. [PMID: 19528037 DOI: 10.1136/gut.2009.180711]
76. Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzalez FJ, Samid D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 1996; 52: 659-667. [PMID: 8759039]
77. Svechnikova I, Almqvist PM, Ekström TJ. HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. Int J Oncol 2008; 32: 821-827. [PMID: 18360709]
78. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 2007; 67: 346-353. [PMID: 17210717 DOI: 10.1158/0008-5472.CAN-06-2845]
79. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatinmodifying drugs in human cancer cells. Cancer Cell 2006; 9: 435-443. [PMID: 16766263 DOI: 10.1016/j.ccr.2006.04.020]
80. Ammerpohl O, Trauzold A, Schniewind B, Griep U, Pilarsky C, Grutzmann R, Saeger HD, Janssen O, Sipos B, Kloppel G, Kalthoff H. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 2007; 96: 73-81. [PMID: 17164759 DOI: 10.1038/sj.bjc.6603511]
81. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133: 2485S-2493S. [PMID: 12840228]
82. Mullins TD, Kern HF, Metzgar RS. Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines. Pancreas 1991; 6: 578-587. [PMID: 1946315]
83. Gaschott T, Maassen CU, Stein J. Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells. Anticancer Res 2001; 21: 2815-2819. [PMID: 11724360]
84. Zhang JS, Wang L, Huang H, Nelson M, Smith DI. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells. Genes Chromosomes Cancer 2001; 30: 123-135. [PMID: 11135429]
85. Natoni F, Diolordi L, Santoni C, Gilardini Montani MS. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 2005; 1745: 318-329. [PMID: 16109447 DOI: 10.1016/j.bbamcr.2005.07.003]
86. McIntyre LJ, Kim YS. Effects of sodium butyrate and dimethylsulfoxide on human pancreatic tumor cell lines. Eur J Cancer Clin Oncol 1984; 20: 265-271. [PMID: 6200329]
87. Bensaadi N, Clemente F, Vaysse N. Modulation of enzymatic activities during spontaneous and induced differentiation in a human pancreatic adenocarcinoma cell line CAPAN-1. Int J Pancreatol 1989; 4: 391-406. [PMID: 2543714]
88. Bloom EJ, Siddiqui B, Hicks JW, Kim YS. Effect of sodium butyrate, a differentiating agent, on cell surface glycoconjugates of a human pancreatic cell line. Pancreas 1989; 4: 59-64. [PMID: 2717602]
89. Parekh D, Ishizuka J, Townsend CM, Haber BE, Beauchamp RD, Rajaraman S, Karp G, Hsieh J, Thompson JC. Differential effects of sodium butyrate and hexamethylene bisacetamide on growth and secretion of cultured human endocrine tumor cells. Arch Surg 1991; 126: 467-472. [PMID: 1706915]
90. Estival A, Clerc P, Vaysse N, Tam JP, Clemente F. Decreased expression of transforming growth factor alpha during differentiation of human pancreatic cancer cells. Gastroenterology 1992; 103: 1851-1859. [PMID: 1451978]
91. Ide Y, Miyoshi E, Nakagawa T, Gu J, Tanemura M, Nishida T, Ito T, Yamamoto H, Kozutsumi Y, Taniguchi N. Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. Biochem Biophys Res Commun 2006; 341: 478-482. [PMID: 16434023 DOI: 10.1016/j.bbrc.2005.12.208]
92. el-Deriny SE, O'Brien MJ, Christensen TG, Kupchik HZ. Ultrastructural differentiation and CEA expression of butyrate-treated human pancreatic carcinoma cells. Pancreas 1987; 2: 25-33. [PMID: 3575313]
93. Corra S, Kazakoff K, Mogaki M, Cano M, Pour PM. Modification of antigen expression in human and hamster pancreatic cancer cell lines induced by sodium butyrate. Teratog Carcinog Mutagen 1993; 13: 199-215. [PMID: 7905674]
94. Miszczuk-Jamska B, Merten M, Renaud W, Guy-Crotte O, Figarella C. Trypsinogen expression by two human pancreatic cell lines CFPAC-1 and CAPAN-1. Modulation during spontaneous and induced cell growth. Int J Pancreatol 1994; 16: 61-69. [PMID: 7806913]
95. Egawa N, Maillet B, VanDamme B, De Grève J, Klöppel G. Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines. Virchows Arch 1996; 429: 59-68. [PMID: 8865855]
96. Farrow B, Rychahou P, O'Connor KL, Evers BM. Butyrate inhibits pancreatic cancer invasion. J Gastrointest Surg 2003; 7: 864-870. [PMID: 14592659]
97. Yeh TS, Tseng JH, Liu NJ, Chen TC, Jan YY, Chen MF. Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg 2005; 140: 1184-1190. [PMID: 16365240 DOI: 10.1001/archsurg.140.12.1184]
98. Speranza A, Pellizzaro C, Coradini D. Hyaluronic acid butyric esters in cancer therapy. Anticancer Drugs 2005; 16: 373-379. [PMID: 15746573]
99. Pellizzaro C, Speranza A, Zorzet S, Crucil I, Sava G, Scarlata I, Cantoni S, Fedeli M, Coradini D. Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report. Pancreas 2008; 36: e15-e23. [PMID: 18437074 DOI: 10.1097/MPA.0b013e31816705bc]
100. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. Int J Biochem Cell Biol 2007; 39: 1388-1405. [PMID: 17383217 DOI: 10.1016/j.biocel.2007.02.009]
101. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-4597. [PMID: 10200307]
102. Baradari V, Huether A, Höpfner M, Schuppan D, Scherübl H. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer 2006; 13: 1237-1250. [PMID: 17158768 DOI: 10.1677/erc.1.01249]
103. Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 2011; 20: 823-829. [PMID: 21554162 DOI: 10.1517/13543784.2011.577737]
104. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 2007; 121: 1138-1148. [PMID: 17455259 DOI: 10.1002/ijc.22751]
105. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008; 7: 759-768. [PMID: 18413790 DOI: 10.1158/1535-7163.MCT-07-2026]
106. Bonfils C, Kalita A, Dubay M, Siu LL, Carducci MA, Reid G, Martell RE, Besterman JM, Li Z. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008; 14: 3441-3449. [PMID: 18519775 DOI: 10.1158/1078-0432. CCR-07-4427]
107. Liang S, Yang ZL. Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats. Zhongnan Daxue Xuebao Yixueban 2007; 32: 109-113. [PMID: 17344598]
108. Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H, Maruta H. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). Cancer Lett 2007; 245: 242-251. [PMID: 16540233 DOI: 10.1016/j.canlet.2006.01.018]
109. Hess-Stumpp H, Apetri E, Hoffmann J. MS-275, a potent orally active inhibitor of histone deacetylases, is efficacious in a wide range of experimental tumors: In vivo efficacy data. Proc Am Ass Cancer Res 2005; 46: 607
110. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by.4-(acetylamino)-N (2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther 2003; 2: 401-408. [PMID: 12700284]
111. LoRusso PM, Demchik L, Foster B, Knight J, Bissery MC, Polin LM, Leopold WR, Corbett TH. Preclinical antitumor activity of CI-994. Invest New Drugs 1996; 14: 349-356. [PMID: 9157069]
112. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP, Schabel FM. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44: 717-726. [PMID: 6692374]
113. Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 2008; 14: 3681-3692. [PMID: 18595135]